Philip A. DeSimone, M.D.
Professor of Medicine
Philip A. DeSimone, M.D.
Professor of Medicine
Clinical Interests: Gastrointestinal Cancers, Colorectal Cancer, Melanoma
I. Certifications/Licensure:
1972: Internal Medicine
1974: Hematology
Kentucky License Number: 15703
II. Education:
1963: Bachelor of Arts, Biology
University of New Hampshire
1967: Medical Doctor
University of Vermont, College of Medicine
1968: Internal Medicine Internship
University of Kentucky Medical Center
1970: Captain/Combat Flight Surgeon
U.S. Army
Served 1 year Vietnam
1972: Internal Medicine Residency
University of Kentucky Medical Center
1974: Fellowship in Hematology
University of Kentucky Medical Center
1988: Program for Chiefs of Clinical Service
Harvard School of Public Health
1990: Advanced Program: Chiefs of Clinical Services
Harvard School of Public Health
III. Professional Experiences and Academic Appointments:
1995-2000: Associate Chairman for University of Kentucky Veterans Affairs
1989-1994: Assistant Dean for Ambulatory Care, University of Kentucky
1989-2007: Professor of Medicine University of Kentucky
2000-2004: Director, Division of Hematology, Oncology, and Blood & Marrow Transplant, University of Kentucky
2000-2004: Associate Director for Clinical Affairs, University of Kentucky
2004 - 2006: Medical Director of Rural Cancer, University of Kentucky
2004 - present: Director, Post Graduate Educational Training Program, University of Kentucky
2006: President and CEO, Markey Cancer Center Foundation
2007 - present: Part Time Faculty, University of Kentucky
IV. Honors and Awards:
1987: Clinical Clerkship Teaching Award, University of Kentucky
1989: Clinical Gold Apple Teaching Award, University of Kentucky
1990: President Faculty Grant Award (3 year monetary award)
1991: Clinical Gold Apple Teaching Award, University of Kentucky
1994: Master Teacher Award in Leadership and Teaching
1997: Master Teaching Award in Innovation
1998: Kentucky Laureate Award, American College of Physicians
V. Professional Activity:
Memberships in Professional Societies
American College of Physicians
Member, American College of Physician Executives
Member, American Association for Cancer Education
Member, Academy of Hospice Physicians
Member, American Society for Clinical Oncology
Member, American Medical Association
Member, Southern Medical Association
Member, Kentucky Medical Group Management Association
Member, American Society of Hematology
Member, European Society of Hematology
Member, National Integrative Medicine Council
VI. Research and Presentations:
Sharma A, Mani S, Hanna N, Guha C, Vikram B, Weichselbaum RR, Sparano J, Sood B, Lee D, Regine W, Mohiuddin M, Valentino J, Herman J, DeSimone P, Arnold SM, Carrico J, Rockich AK, Warner-Carpenter J, Barton-Baxter M. Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther 2001 Jun 10; 12(9): 1109-31.
Halepota M, Mohiuddin M, Desimone P, Ahmed MM. Durable Local Responses With Sub therapeutic Doses of Concurrent Radiation and Gemcitabine in a Patient With Refractory Hodgkin’s Disease. Clinical Advances in Hematology & Oncology, 1(7):413-5, 2003.
Arnold SM, Regine WF, Ahmed MM, Valentino J, Spring P, Kudrimoti M, Kenady D, DeSimone P, Mohiuddin M. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: Results of a new treatment paradigm. International Journal of Radiation Oncology, Biology and Physics 58(5):1411-7, 2004.
Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA, Smith DA, Koch KM, Stead AG, Mangum S, Bowen CJ, Spector NL, Hsieh S, Adams VR. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23(1):39-49, 2005.
Ataga KI, Orringer EP, Styles L, Vickinsky EP, Swerdlow P, Davis GA, DeSimone PA, Stocker. Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy 26(11):1557-64, 2006.
Sapp CM, DeSimone P. Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. Clin Colorectal Cancer 6(5):382-5, 2007.
Kelly KM, Shedlosky-Shoemaker R, Porter K, Remy A, DeSimone P, Andrykowski MA. Cancer family history reporting: Impact of method and psychosocial factors. Journal of Genetic Counseling 16(3):373-82, 2007.
* For a complete list of current and past funding, advisory board positions, and publications, please e-mail Meredith Boarman at mtboar2@uky.edu.
|
